{"protocolSection":{"identificationModule":{"nctId":"NCT06481904","orgStudyIdInfo":{"id":"OBS18117"},"secondaryIdInfos":[{"id":"U1111-1306-6690","type":"REGISTRY","domain":"ICTRP"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Registry for Stage 2 Type 1 Diabetes","officialTitle":"An Observational, Long-term Safety Study of TZIELD® (Teplizumab-mzwv) in Patients With Stage 2 Type 1 Diabetes"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-26","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2037-01-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2037-01-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-26","studyFirstSubmitQcDate":"2024-06-26","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-26","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true},"descriptionModule":{"briefSummary":"Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin.\n\nTZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D.\n\nThe purpose of this study is to collect general information on patients with stage 2 T1D and further information on the long-term effects of TZIELD® in patients with Stage 2 T1D, treated as per standard of care."},"conditionsModule":{"conditions":["Type 1 Diabetes"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":200,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"TZIELD group","description":"Patients prior to the initiation of TZIELD treatment or initiated TZIELD treatment within 6 months to study enrollment","interventionNames":["Drug: TZIELD (teplizumab-mzwv)"]},{"label":"Comparator group","description":"Patients not planned to be treated"}],"interventions":[{"type":"DRUG","name":"TZIELD (teplizumab-mzwv)","description":"This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.","armGroupLabels":["TZIELD group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of adverse events of special interests (AESI)","description":"Presence of AESIs including cytokine release syndrome (CRS), serious infections, hypersensitivity reactions, lymphoproliferative disorders, and malignancies","timeFrame":"Throughout the study, approximately 10 years"},{"measure":"Number of serious adverse events (SAE)","timeFrame":"Throughout the study, approximately 10 years"},{"measure":"Number of adverse events (AE) in mothers, fetuses, and infants exposed to TZIELD during pregnancy","timeFrame":"From start of pregnancy to 12 months post-partum"},{"measure":"Number of maternal pregnancy-related events","timeFrame":"From start of pregnancy to 12 months post-partum"},{"measure":"Developmental outcomes of the infant","timeFrame":"From birth of infant to 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nTZIELD-Exposed Cohort\n\n* Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment:\n* Day 1: 65 mcg/m2\n* Day 2: 125 mcg/m2\n* Day 3: 250 mcg/m2\n* Day 4: 500 mcg/m2\n* Days 5 through 14: 1,030 mcg/m2 per day\n* Cumulative dose is approximately 11,240 mcg/m2\n* Appropriate written informed consent/assent as applicable for the age of the patient\n\nTZIELD-Unexposed Cohort\n\n* Patients in the US diagnosed with Stage 2 T1D but who are not treated with TZIELD\n* Appropriate written informed consent/assent as applicable for the age of the patient\n\nExclusion Criteria:\n\n* Patients who initiated TZIELD treatment more than 6 months prior to enrollment\n* Patients who had participated in a previous clinical trial for TZIELD\n* Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"],"studyPopulation":"Patients in the US diagnosed with Stage 2 Type 1 Diabetes","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Trial Transparency email recommended (Toll free for US & Canada)","role":"CONTACT","phone":"800-633-1610","phoneExt":"option 6","email":"Contact-US@sanofi.com"}],"overallOfficials":[{"name":"Clinical Sciences & Operations","affiliation":"Sanofi","role":"STUDY_DIRECTOR"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000003920","term":"Diabetes Mellitus"},{"id":"D000003922","term":"Diabetes Mellitus, Type 1"}],"ancestors":[{"id":"D000044882","term":"Glucose Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000004700","term":"Endocrine System Diseases"},{"id":"D000001327","term":"Autoimmune Diseases"},{"id":"D000007154","term":"Immune System Diseases"}],"browseLeaves":[{"id":"M7115","name":"Diabetes Mellitus","asFound":"Diabetes","relevance":"HIGH"},{"id":"M7117","name":"Diabetes Mellitus, Type 1","asFound":"Type 1 Diabetes","relevance":"HIGH"},{"id":"M11639","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M25403","name":"Glucose Metabolism Disorders","relevance":"LOW"},{"id":"M7862","name":"Endocrine System Diseases","relevance":"LOW"},{"id":"M4629","name":"Autoimmune Diseases","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"}]}},"hasResults":false}